Brief: Jasper Therapeutics Announces Development Prioritization Of Briquilimab In Chronic Diseases

Jasper Therapeutics

10/01/2023 14:16

Jan 10 (Reuters) - Jasper Therapeutics Inc  JSPR.O :
    * JASPER THERAPEUTICS ANNOUNCES DEVELOPMENT PRIORITIZATION
OF
BRIQUILIMAB IN CHRONIC DISEASES, INCLUDING URTICARIA AND
LOWER-RISK MDS, AND STEM CELL TRANSPLANT FOR SICKLE CELL DISEASE
AND OTHER RARE DISEASES
    * JASPER THERAPEUTICS : AS PART OF OVERALL PORTFOLIO
PRIORITIZATION, COMPANY WILL FOCUS ON DEVELOPMENT OF ITS LEAD
PRODUCT CANDIDATE, BRIQUILIMAB
    * JASPER THERAPEUTICS INC: COMPANY DOES NOT HAVE ANY
NEAR-TERM
PLANS TO INITIATE A PHASE 3 STUDY IN AML/MDS OF THE DRUG
    * JASPER THERAPEUTICS: COMMITTED TO EXPLORING BRIQUILIMAB'S
LONG-TERM POTENTIAL TO BECOME LEADING ANTIBODY TARGETING C-KIT
FOR USE AS STANDALONE THERAPY

Source text for Eikon:  ID:nGNX2H5StT 
Further company coverage:  JSPR.O 
 ((Reuters.Briefs@thomsonreuters.com;))